APA (7th ed.) Citation

R, W., H, S., H, H., Y, K., R, O., R, S., & T, M. (2024). Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor. Journal of pharmaceutical sciences, 113(3), 798. https://doi.org/10.1016/j.xphs.2023.09.016

Chicago Style (17th ed.) Citation

R, Watari, Sawada H, Hashimoto H, Kasai Y, Oka R, Shimizu R, and Matsuzaki T. "Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor." Journal of Pharmaceutical Sciences 113, no. 3 (2024): 798. https://doi.org/10.1016/j.xphs.2023.09.016.

MLA (9th ed.) Citation

R, Watari, et al. "Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor." Journal of Pharmaceutical Sciences, vol. 113, no. 3, 2024, p. 798, https://doi.org/10.1016/j.xphs.2023.09.016.